ExeVir

Happy to have you onboard Prakash Bhuyan! Looking forward to achieving great impact together! #immunocompromised #InfectiousDiseases #COVID19 #longCovid #AntibodyTechnology #Prevention #VariantProof ExeVir

🚀 Exciting News! 🚀 Happy to confirm that ExeVir will be attending the World Vaccine Conference as a pioneering start-up! 🌍💉 A huge thank you to the The World Vaccine Congress for this opportunity. We can't wait to connect with industry leaders, innovators and researchers, and share how our cutting-edge single-domain (VHH-Fc) antibodies are revolutionizing the fight against infectious diseases. 🌟🔬 Stay tuned for more updates and see you there! 👋✨ #WorldVaccineConference #InnovationInHealthcare #Exevir #InfectiousDiseases #Biotech

🚀 Exciting News! 🚀 Happy to confirm that ExeVir will be attending the World Vaccine Conference as a pioneering start-up! 🌍💉 A huge thank you to the The World Vaccine Congress for this opportunity. We can't wait to connect with industry leaders, innovators and researchers, and share how our cutting-edge single-domain (VHH-Fc) antibodies are revolutionizing the fight against infectious diseases. 🌟🔬 Stay tuned for more updates and see you there! 👋✨ #WorldVaccineConference #InnovationInHealthcare #Exevir #InfectiousDiseases #Biotech

As highlighted in this NPR article, the risk of dengue fever is increasing, particularly for travelers. Seems not only the mosquito is to blame: Human mobility, either short or longer distances, plays a significant role in moving the virus around. Humans can be the vector, the ones that are moving the virus even a longer distance than mosquitoes. Infected travelers can bring the virus back home, potentially starting a new chain of transmission through local mosquitos. At ExeVir, we are committed to addressing this urgent public health challenge by developing highly potent anti-dengue heavy chain-only (VHH-Fc) bispecific antibodies with a disruptive mode of action that have the potential to provide immediate protection for travelers to endemic regions. Stay informed and join us in our mission to make a difference. #dengue #mosquitoes #infectiousdiseases #travel https://lnkd.in/eazBs7kr

June 15 was #worlddengueday! This virus was rightly named a top ten threat to global health and classified as a Grade 3 emergency by WHO recently. As cases continue to surge across the world, with an unprecedented number of infections in the Americas since the beginning of this year, the WHO has launched a new dashboard to strengthen global tracking. So far, it contains data from 103 countries.  https://lnkd.in/dZsXk5-x   Innovation provides hope, and we at ExeVir are developing highly potent anti-dengue heavy chain-only (VHH-Fc) bispecific antibodies with a disruptive mode of action that have the potential to provide immediate protection in an outbreak setting. #WorldDengueDay #FightDengue #GlobalHealth ExeVir #WHO   https://lnkd.in/e2Gfw_cP

Multiple indicators monitoring Covid-19 cases in the US indicate growing numbers of SARS-CoV-2 infections in many regions of the country. The new variants KP.2 (with spike substitutions R346T, L455S, F456L, and V1104L) and KP.3 (Q493E, L455S, F456L and V1104L) are likely behind the new Covid-19 cases. #covid19 #USA #CDC #publichealth #medicine #infectiousdiseases https://lnkd.in/gD4RbDSz

Happy to announce that our Chief Scientific Officer, Viki Bockstal, will be presenting at the Flanders Vaccine Pitch&Match event! 🧬💉 Join us to hear Viki’s insights on the latest advancements of our COVID-19 program and the clinical candidate XVR013m, a variant-proof antibody with exceptional potency to prevent and treat COVID-19 in the target populations of immunocompromised and elderly. This is a great opportunity to learn about ExeVir's cutting-edge innovations that are shaping the future of healthcare and disease prevention. Don't miss out on this chance to connect with us and collaborate to reach our mission! #AntibodyTechnology #COVID19 #Prevention #VariantProof #Immunocompromised #Healthcare #FlandersVaccine

In light of this week’s article in La Libre Belgique on Long COVID affecting over 65 million people, it is clear that ongoing research and innovative treatments are crucial. At ExeVir, we are developing the novel SARS-CoV-2 variant-proof antibody XVR013m that has the ideal profile to be tested in the clinic as potential treatment for Long COVID, offering hope for an effective treatment to the millions of individuals currently suffering from this debilitating disease. Our collaboration with Tomaso Antonacci, president of the Long COVID Belgium Association, highlights our commitment to tackling this ongoing health challenge. Together, we aim to improve outcomes for Long COVID patients and advance global health resilience.   #LongCOVID #HealthInnovation #AntibodyTherapy #PublicHealth #ResearchAndDevelopment #ExeVir ExeVir https://lnkd.in/eVBHqBww

The 7th Asia Dengue conference is officially started. Looking forward to many networking opportunities !

New data on our variant-proof XVR013m antibody has demonstrated its exceptional neutralization activity against the #Covid19 variant JN.1, the parental strain of the most dominant variants currently circulating globally. XVR013m is a heavy chain-only antibody that targets a unique and highly conserved epitope in the S2 subunit of the spike protein. Novel antibody therapeutics are urgently needed to provide the millions of immunocompromised and elderly individuals, who remain at high risk of severe COVID-19 disease despite vaccination, with an additional layer of protection. 🔗 Read our Press Release: https://lnkd.in/evzC4Pwf 🔬 Learn about our unique heavy chain-only antibody technology and latest research: https://lnkd.in/etaU9RJk #Biotech #Pharma #Innovation